Nederlands
HomeHospital Education and TrainingResearch About us
To top
menu
088 75 555 55
View all overviews Hide all overviews

Circulatory Health

UMC Utrecht

The cardiovascular researchers and clinicians from UMC Utrecht have embarked on an ambitious enterprise to realize true multidisciplinary and integrated research and care within the program entitled, “Circulatory Health”. Advancing cardiovascular research for the benefit of patients and the general population requires a multidisciplinary approach, including basic and applied research.

Research areas

The Center for Circulatory Health portfolio consists of nine research areas. In each area, a different methodological approach is applied to gain knowledge and insights about patients and diseases, resulting in improved prediction, prognosis and prevention. Every research area covers a range of patient groups. THe research areas do not operate separately, but collaborate and interact, offering opportunities for cross-fertilization between findings and clinical applications. On this website we present our nine multidisciplinary research areas: Proteomics and Biomarkers, Genetics, Molecular and Cellular Biology, Metabolism, Imaging, Clinical Interventions and Therapeutic Innovations, Clinical Research Methods, Prevention and Public Health and Cardiovascular Regenerative Medicine.

organization and background

Cardiovascular disease continues to have extensive impact worldwide. Despite many advances in prevention, intervention, and treatment, diseases affecting the circulatory system maintain a significantly high disease burden. Cardiovascular disease remains the number one cause of death among women and the second leading cause of death in men.

The challenges we face are multifaceted; an aging population, and the rise in cardiovascular risk factors- such as obesity and diabetes. To face these challenges our teams within the UMC Utrecht Circulatory Health employ multidisciplinary, integrated approach to advancing cardiovascular research and care.

Prof. dr. Rick Grobbee

Diederick E. (Rick) Grobbee is Professor of Clinical Epidemiology at the UMC Utrecht and member of the program committee of the Center for Circulatory Health and within this program he's chair of the steering committee care. He is also Chief Scientific Officer at Julius Clinical.

Rick Grobbee has been a (principal) investigator in many large-scale epidemiologic studies and randomized intervention trials relating to the prevention and treatment of cardiovascular disease. His experience covers the full range of study designs including trials, cohorts and case-control studies. In addition, he has worked on theoretical principles and methods of diagnostic and prognostic research.

 

News

Calendar

1st Translational Cardiovascular Research Meeting

Jun
29
Time: 0:00 Location: Utrecht

Publications

PhD Defenses

PhD Defense L.M. Verberne MSc

Aug
31
Time: 14:30 Location: Utrecht University

Follow us on Twitter: @CirculatHealth

societal relevance

Julius Clinical: Independent drug research

The Circulatory Health program created significant societal impact with the spin-off company Julius Clinical. This academic research organization conducts national and international phase IIb-IV clinical trials. Since 2007, over 50 trials across more than 700 sites globally have been carried out.

Julius Clinical is not a traditional contract research organization. Our academic roots guarantee independence and secure trust from patients, doctors and society as a whole. The company insists on independently analyzing and reporting of the data.

Three of the largest and most prestigious projects are the Alecardio project, the CAPITA trial and the Advance-project. The Alecardio trial tests the effect of aleglitazar in about 7,000 patients with type 2 diabetes who experienced a recent acute coronary syndrome event.

The CAPITA trial establishes the efficacy of a pneumococcal vaccine in preventing a first episode of community acquired pneumonia. In the Advance project, routine antihypertensive therapy and glucose control therapy was compared in 11,000 type 2 diabetes patients.

A strip of pills

 

A doctor looking at a sample


Platform for open innovation in cardiovascular biomarker research

Principal investigators of the Circulatory Health program in the field of biomarker research have taken the initiative to bring academia and industry together at an early stage. Their ambition is to develop a pro-active platform between science and industry. The proposed platform

  •     Provides companies with a continuous insight into the combined portfolio of Dutch research in the field of cardiovascular biomarkers from bench to bedside
  •     Translates R&D issues in the private sector to collaborative research agendas and contract research at academic centers.
  •     Ultimately, this platform aims to facilitate faster technology transfer in a specialized field throughout the value chain

We seek to create healthy partnership thereby fueling innovation and delivery, directly leading to expanded economic and social value.

Universitair Medisch Centrum Utrecht © 2017 Universitair Medisch Centrum Utrecht

Deze website maakt gebruik van cookies

Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. U kunt dan geen video’s op deze website zien. Wij plaatsen zelf ook cookies om onze site te verbeteren. Deze gegevens worden niet aan derden verstrekt. Lees meer over het cookiebeleid.